Zepbound for sleep apnea: what the approval actually covers

On 20 December 2024 the FDA approved Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. That sentence is the whole indication. It is not a license to stop CPAP. The prescribing information states that the OSA trials did not evaluate when, or whether, to discontinue PAP in people who had been using it.

What did the FDA actually approve?

Lilly’s U.S. Prescribing Information, revised April 2026 as retrieved for this article, lists two indications, both “in combination with a reduced-calorie diet and increased physical activity”: long-term weight reduction in adults with obesity, or overweight plus a weight-related comorbid condition; and treatment of moderate to severe OSA in adults with obesity. The limitation of use is that Zepbound contains tirzepatide and should not be coadministered with other tirzepatide products or with a GLP-1 receptor agonist.

Section 1 does not print an AHI number or a BMI integer in the OSA bullet. “Adults with obesity” is the labeled population. The clinical-studies section (14.2) defines how the trials were run: AHI of 15 or higher and BMI of 30 kg/m² or higher, without type 2 diabetes. Do not write “the label requires AHI ≥ 15” as if that integer sat in section 1. It is how moderate to severe OSA was operationalized in SURMOUNT-OSA.

The American Academy of Sleep Medicine’s industry note (updated 9 January 2025) called Zepbound the first FDA-approved medication for OSA and pointed to the same December 20 announcement. First-in-class is a regulatory fact. It is not a ranking of effectiveness against CPAP therapy.

Why is this not a CPAP replacement?

SURMOUNT-OSA was two 52-week trials under one master protocol (NCT05412004). Study 5 enrolled 234 adults with moderate to severe OSA and obesity who were unable or unwilling to use PAP. Study 6 enrolled 235 who were already on PAP (233 treated; two randomized people did not receive drug). Everyone received diet and activity counseling. The drug arms used a maximum tolerated dose of 10 mg or 15 mg weekly after escalation.

Study 6 participants were instructed to suspend PAP for 7 days before the primary AHI assessment. That is a measurement method so the PSG can see residual events without the mask on. It is not a clinical instruction to abandon PAP at home. The USPI says the OSA studies “did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy.” If someone tells you the approval means you can box the machine, they did not read section 14.2.

PAP remains first-line mechanical treatment for moderate to severe obstructive apnea. Tirzepatide is labeled as an adjunct to diet and activity for OSA in adults with obesity. People in Study 6 were on PAP at enrollment and planned to continue it during the trial. People in Study 5 were not using it. Your category is an office visit, not a blog self-sort.

What did SURMOUNT-OSA show on AHI?

USPI Table 9 (mITT) reports least-squares mean AHI change at week 52:

• Study 5 (not on PAP): Zepbound −25.3 events per hour versus placebo −5.3. Difference −20.0 (95% CI −25.8 to −14.2).
• Study 6 (on PAP): Zepbound −29.3 versus placebo −5.5. Difference −23.8 (95% CI −29.6 to −17.9).

Baseline mean AHI in the overall Study 5 / Study 6 populations was 51.5 and 49.5 events per hour. Mean BMI was 39.1 and 38.7. A 25-point drop from a baseline near 50 is still a residual AHI that can sit in the moderate range. The label also reports the share who reached AHI under 5, or AHI 5 to 14 with Epworth score of 10 or less: 42.2% on drug versus 15.9% placebo in Study 5, and 50.2% versus 14.3% in Study 6. Those are not “cured of sleep apnea” rates. They are a composite the sponsor defined.

Weight change in the same table: −17.7% versus −1.6% in Study 5, and −19.6% versus −2.3% in Study 6. AASM’s rounded patient summary was 25 to 29 fewer events per hour versus 5 to 6 with placebo, and 18% to 20% body-weight loss versus about 2%. Use the table when you need the decimal; use AASM when you need the plain-language range. Neither source says the apnea is gone.

How is it dosed for OSA?

For all indications, including OSA, the starting dose is 2.5 mg subcutaneously once weekly for 4 weeks. The USPI states that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. After 4 weeks the dose goes to 5 mg. Further 2.5 mg steps are allowed after at least 4 weeks on the current dose. For OSA the recommended maintenance dose is 10 mg or 15 mg once weekly. The maximum for every indication is 15 mg once weekly. Escalation in the trials took up to 20 weeks to reach 10 or 15 mg.

Skipping straight to 15 mg because a friend did is not the label. Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) are the common reason titration exists. The boxed warning is thyroid C-cell tumors in rats; Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN2.

Diet and activity are not optional flavor text. Section 2.4 repeats that Zepbound is administered in combination with a reduced-calorie diet and increased physical activity. A prescription without that plan is off the labeled use even if the AHI matches the trial.

Who is this for, and who is it not for?

Adults with obesity and moderate to severe OSA, after a real sleep study, in a clinic that will keep PAP in the conversation if PAP is still indicated. It is not approved in this indication for people who are not obese. It was not studied in these two trials in people with type 2 diabetes (those people may already be on tirzepatide as Mounjaro, which is a different labeled product; the USPI says not to combine tirzepatide products).

It does not replace the workup for sleep apnea. Snoring plus a high BMI is not a diagnosis. If the question is whether you even have OSA, test first. If the question is whether you qualify for the OSA indication versus the weight-reduction indication, that split matters for insurance and is a separate article.

Do not treat Zepbound as an Inspire alternative on a flowchart you found online. Genio’s FDA indication names pharmacotherapy such as tirzepatide as a standard-of-care step some implant candidates must have failed or been ineligible for. That is Genio’s label, not Zepbound’s. The drug page should stay on the drug.

What should you do with this information?

Read the indication again: moderate to severe OSA, adults with obesity, with diet and activity, not as a PAP substitute. If that describes you, the next step is a visit, not a coupon. Westerville Sleep Center can review the sleep study, the current PAP download if you have one, and whether a tirzepatide prescription for the OSA indication is medically appropriate. Prescribing, prior authorization, and follow-up AHI testing are clinical decisions. This page is not a prescription.

Call (614) 898-9340, Monday through Friday, 8:00 AM to 5:00 PM. The office is at 450 Alkyre Run Drive, Suite 230, Westerville, OH 43082. For treatment-page detail already on the site, see Zepbound. Bring the PSG or home-test report. Do not put a condition name or a symptom list into a website form.